Evolus: Smooth Progress As Management Targets $700m Aesthetics Franchise Revenues By 2028

Svitlana HulkoInvestment Overview Evolus (NASDAQ:EOLS) went public in February 2018, its initial public offering ("IPO") raising ~$$60m in gross proceeds, at a price of $$12 per share. The company describes itself as "global performance beauty company with a customer-centric approach to delivering breakthrough products", in its 2023 annual report/10K submission, and its first and only commercial product, Jeuveau, was approved in the US and most European territories (where it is marketed and sold as Nuceiv ...